Content area
Abstract
In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Details
Title
Plerixafor
Author
Dipersio, John F; Uy, Geoffrey L; Yasothan, Uma; Kirkpatrick, Peter
Pages
105-6
Publication year
2009
Publication date
Feb 2009
ISSN
14741776
e-ISSN
14741784
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
223590637
Copyright
Copyright Nature Publishing Group Feb 2009